Skip to main content

Helping patients with recurrent vulvovaginal candidiasis

A new oral antifungal (oteseconazole) specifically indicated for the treatment of RVVC was approved in the United States in April 2022 and is currently on fast-track, priority review by Health Canada.

Register for free access or login.

Canadian Healthcare Network is an independent online community for Canadian healthcare professionals in medicine and pharmacy. It is the online home of the Medical Post and Pharmacy Practice + Business.

Membership is free and allows doctors, pharmacists, nurses and many others to get the latest breaking news, updates on clinical guidelines and read (and even write) commentary from your healthcare peers.

More Blog Posts in This Series

X
This ad will auto-close in 10 seconds